New Delhi : BSE Shares of Sun Pharmaceutical up 2.87 percent on the back of USFDA approval for ezetimibe tablets. Sun’s wholly owned subsidiary has finally got approved by the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for a generic version of Zetia, (ezetimibe) tablets 10mg.
Ezetimibe, generic version of Zetia will be used to lower cholesterol in the blood. According to market reports Zetia has $2.7 billion of the market in the US and this success is very progressive for Sun Pharmaceutical Company.
Ezetimibe works by reducing the amount of cholesterol absorbance in an individual’s body from the diet. Sun Pharma is under performing and one-year performance is 28.04 percent down.
Zydus Cadila has also received the final US FDA approval to market ezetimibe tablets USP, 10 mg, used to reduce high cholesterol levels. The estimated sale for ezetimibe tablets is $2.7 billion as per IMS MAT April 2017.
